After waiting years for justice, many Purdue opioid victims are defeated — by paperwork For years, individuals harmed by Purdue Pharma’s OxyContin have waited for compensation through the company’s bankruptcy settlement. Despite the approval of a $7.4 billion plan in late 2024, fewer than half of the nearly 140,000 claimants will receive any payment, according to an investigation by ProPublica and The Philadelphia Inquirer. The primary barrier? Documentation requirements that prove victims took a Purdue-manufactured opioid — a challenge made nearly impossible by the passage of time and gaps in medical records. The settlement includes $870 million set aside for individual victims, but accessing these funds requires claimants to demonstrate a direct link between their injury and a specific Purdue product. However, as reported by Reuters, doctors’ records typically list the drug prescribed — such as “oxycodone” — but not the manufacturer. This distinction becomes critical years later when patients attempt to verify they ingested OxyContin, the brand-name opioid produced by Purdue, rather than a generic version made by another company. Mary Jannotta, a former supermarket deli worker from the Philadelphia suburbs, exemplifies this struggle. After developing chronic pain from years on her feet and a failed back surgery in 2008, her doctor repeatedly prescribed OxyContin. She later became dependent, lost her home and car and saw her grandson Tyler Cordeiro die of an overdose at age 24 after misusing her prescription pills. Like nearly 140,000 others, Jannotta filed a claim when Purdue entered bankruptcy in 2019. Yet under the current settlement terms, she may be excluded not as her suffering is in question, but because she cannot produce paperwork proving the pills she took were manufactured by Purdue. Legal experts note that this evidentiary hurdle disproportionately affects long-term users, elderly patients, and those who received care from providers who no longer maintain accessible records. In many cases, pharmacies have destroyed prescription logs after the legally required retention period, and prescribing physicians have retired or passed away, leaving no one to verify the origin of the medication. The initial bankruptcy settlement was rejected by the U.S. Supreme Court in 2024 because it attempted to shield the Sackler family — Purdue’s owners — from future opioid-related lawsuits. The revised plan, approved by a federal judge in November 2024, was promoted as the first opioid settlement to meaningfully compensate individual victims. However, advocates argue that its strict documentation rules undermine that promise, effectively shutting out tens of thousands of legitimate claimants who lack the administrative paper trail to prove their case. As the April 25, 2026, deadline for claim submissions approaches, victim advocacy groups continue to call for reforms to the claims process, including broader acceptance of pharmacy records, sworn affidavits, and prescribing patterns as evidence of Purdue product use. Without such adjustments, many who waited years for justice may uncover themselves defeated not by lack of merit, but by missing paperwork.
Related reading